Seventy-two percent of device postmarket approval and surveillance studies mandated by FDA between 2008 and 2015 are sill ongoing, according to a recent report from the Government Accountability Office. The agency cited patient enrollment as a cause for delay in postmarket device studies, a barrier that agency officials have said could be solved through more widespread use of registries. Some stakeholders have questioned whether FDA has the necessary resources to properly monitor the growing shift to postmarket requirements, a shift...